APPILI THERAPEUTICS INC News

Appili Therapeutics Announces Additional Bridge Loan From Bloom Burton & Co.

Yahoo FinanceApr 26 19:03 ET

Aditxt Signs Agreement to Acquire Appili Therapeutics

Seeking AlphaApr 2 08:51 ET

Appili Therapeutics Reports Q3 Results

Seeking AlphaFeb 14 08:37 ET

Appili Therapeutics Says Patent Issued For Biodefence Vaccine Candidate ATI-1701, Provides Update on Bridge Loan

Appili Therapeutics Inc. (APLI.TO) on Friday said the United States Patent and Trademark Office (USPTO) has published patent claims for ATI-1701. The patent covers the composition and preparation methods for the vaccine through 2039.

MT NewswiresDec 15, 2023 08:18 ET

Appili Therapeutics Announces U.S. FDA Approval of LIKMEZ (ATI-1501) Metronidazole Oral Suspension

FDA approves LIKMEZ as the brand name for Metronidazole Oral Suspension (LIKMEZ is a Trademark of Saptalis Pharmaceuticals, LLC) Currently LIKMEZ is the only liquid oral suspension of metronidazole approved in the

BusinesswireSep 25, 2023 07:54 ET

Appili Therapeutics GAAP EPS of -C$0.01

Seeking AlphaAug 11, 2023 17:45 ET

Press Release: Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2024

Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced its financial and operational results for the first quarter of its fiscal year 2024, which ended on June 30, 2023.

Dow JonesAug 11, 2023 16:50 ET

Appili Therapeutics – Press Release Correction

Appili Therapeutics Inc. (TSX:APLI, OTCQB:APLIF) (the "Company" or "Appili"), announced today a correction to its press release entitled "Appili Therapeutics Reports Fiscal Year 2023 Financial and Operational Results"

BusinesswireJun 23, 2023 17:07 ET

Appili Therapeutics Net Loss of $0.08 Per Share For FY 2023

Appili Therapeutics Inc. (APL.TO), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, on Friday announced its financial and operational results for the fiscal year ended March 31, 2023.

MT NewswiresJun 23, 2023 08:02 ET

Appili Therapeutics GAAP EPS of -C$0.08

Seeking AlphaJun 23, 2023 07:44 ET

Appili Therapeutics Announces Issuance of Patent for ATI-1501 Liquid Oral Reformulation of Metronidazole

Upcoming PDUFA date of September 23, 2023 Appili Therapeutics Inc. (TSX:APLI, OTCQB:APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense,

BusinesswireMay 24, 2023 07:19 ET

Appili Therapeutics Secures Contract for ATI-1701 Funding From U.S. Air Force Academy

Appili Therapeutics Inc. (APLI.TO), focused on drug development for infectious diseases and biodefense, on Monday said it has executed the initial contract with the U.S. Air Force Academy (USAFA) for the previously announced funding of the ATI-1701 program.

MT NewswiresMay 8, 2023 08:45 ET

Appili Therapeutics Appoints Dr. Gary Nabors as Chief Development Officer

Accomplished biopharmaceutical executive brings more than 25 years of experience leading vaccine and antibody product development for infectious disease indications Dr. Nabors representing Appili at the World Vaccine

BusinesswireApr 3, 2023 07:26 ET

Appili Therapeutics Inc. Expected to Post FY2023 Earnings of ($0.08) Per Share (TSE:APL)

Appili Therapeutics Inc. (TSE:APL – Get Rating) – Analysts at Zacks Small Cap increased their FY2023 earnings per share (EPS) estimates for shares of Appili Therapeutics in a research note issued to

Defense WorldFeb 25, 2023 03:43 ET

Appili Therapeutics Appoints Dr. Carl Gelhaus and Arthur Baran to Support the ATI-1701 Biodefense Vaccine Program

Appili Therapeutics has named Dr. Carl Gelhaus as Director of Non-Clinical Research and Arthur Baran as Director of New Product Development for the ATI-1701 program. Appili Therapeutics Inc. (TSX:APLI, OTCQB:APLIF)

BusinesswireJan 17, 2023 07:16 ET

Appili to Get US Patent for Antibiotic ATI-1501

Seeking AlphaJan 13, 2023 07:40 ET

Appili Therapeutics Announces Notice of Allowance From the U.S. Patent and Trademark Office for ATI-1501 Liquid Oral Reformulation of Metronidazole

Anticipated new patent strengthens ATI-1501's potential position as a more convenient alternative treatment option for metronidazole prescriptions on the market. Appili Therapeutics Inc. (TSX:APLI, OTCQB:APLIF) (the

BusinesswireJan 13, 2023 07:21 ET

Appili Therapeutics ATI-1701 Biodefense Vaccine Secures ~$14M of Funding

Seeking AlphaNov 14, 2022 08:15 ET

Appili Therapeutics GAAP EPS of -C$0.04

Seeking AlphaNov 10, 2022 09:49 ET

Appili Therapeutics Inc. (TSE:APL) to Post FY2023 Earnings of ($0.09) Per Share, Zacks Small Cap Forecasts

Appili Therapeutics Inc. (TSE:APL – Get Rating) – Equities researchers at Zacks Small Cap boosted their FY2023 earnings estimates for shares of Appili Therapeutics in a note issued to investors on

Defense WorldSep 5, 2022 01:51 ET